Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for TNBC
NCT05447702Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in triple-negative breast cancer (TNBC), sponsored by West China Hospital of Sichuan University. Started Nov 2022; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05447702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05447702.